CTOs on the Move

Sunovion Pharmaceuticals

www.sunovion.com

 
Sunovion Pharmaceuticals is a Marlborough, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.sunovion.com
  • 84 Waterford Dr
    Marlborough, MA USA 01752
  • Phone: 508.481.6700

Executives

Name Title Contact Details
Daniel Joyce
Senior Director, Information Security and Compliance Profile
Ben Howard
Director - IT Security and Compliance Profile

Jobs

Vice President of Human Resources

Sunovion Pharmaceuticals Massachusetts
Sunovion is hiring a Vice President of Human Resources

Description:

The Vice President of Human Resources will serve as a trusted advisor to the organization on a range of business and organizational issues. The Vice President will lead the design and implementation of human resource strategies, initiatives, ...

Similar Companies

Catalyst Nutraceuticals

Catalyst Nutraceuticals is a family-owned and operated business that specializes in custom manufacturing and formulation of dietary supplements for performance nutrition and wellness brands.

CuraScript

CuraScript is one of the nation's largest providers of specialty injectable and oral medications. CuraScript has been in the specialty pharmacy business since 1989. Between 1994 and August 1, 2000, the company operated as Coram Prescription Services

Nutrishare Inc

Nutrishare Inc is a Elk Grove, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Syros

Syros Pharmaceuticals is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines that control expression of disease-driving genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. Because gene expression is fundamental to the function of all cells, the Company’s gene control platform has broad potential to achieve profound and durable benefit across a range of diseases. Syros is focused on cancer and immune-mediated diseases and is advancing a growing pipeline, including its lead drug candidates SY-1425, a selective RARα agonist for genomically defined subsets of patients identified by its platform, for a range of cancers including acute myeloid leukemia and myelodysplastic syndrome, and SY-1365, a selective CDK7 inhibitor for a range of blood cancers and solid tumors. Led by a team with deep experience in drug discovery, development and commercialization, Syros is located in Cambridge, Mass.